Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recaticimab (SHR-1209) in Non-familial Hypercholesterolemia and Mixed Hyperlipidemia
NCT04885218Phase 3Completed
- Sponsor
- Hengrui
- Start
- Jul 2021
- Primary completion
- May 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of recaticimab in hypercholesterolemia and mixed hyperlipidemia (3 arms), sponsored by Hengrui. Primary endpoint: Percentage change in LDL-C relative to baseline at 24 weeks. Started Jul 2021; status: completed.
02
Drugs
recaticimab
03
Conditions
hypercholesterolemiamixed hyperlipidemia
Beyond the preview
Go deeper on NCT04885218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04885218.